Castuner

The Dime

Bryan Fields

Most cannabis companies won't survive the next three years. The ones that do will have better capital discipline, sharper regulatory reads, and operational frameworks built for compression, not growth. The Dime is where cannabis operators, executives, and investors hear directly from the CEOs and founders making those decisions right now: MSO strategy, state-by-state market dynamics, cultivation and extraction economics, brand positioning, and the financing structures keeping companies alive. Bryan Fields hosts weekly conversations built for operators, not observers.

Сайт подкаста

Слушайте в своём приложении

Эпизоды

309 эпизодов

  1. Europe's 51st State, EU GMP, and Building Before the Market Arrives ft. Michael Sassano 56:18
  2. How AYRLOOM Built Its Advantage in New York Cannabis ft. Eddie Brennan 44:16
  3. Who Benefits From Federal Cannabis Limbo? ft. Jay Rosenthal 53:10
  4. What Makes Consumers Buy the Same Edible Again? ft. Kim Sanchez Rael 42:12
  5. Europe Is Not a Rescue Plan ft. Jamie Pearson 48:03
  6. Paige Figi: The Cannabis Industry Is Cheering A Ban On Medicine 53:21
  7. Understand This Before You Use AI To Build Software ft. Chris Guthrie 50:08
  8. Hirsh Jain: Rescheduling Is Already Picking Winners 1:11:53
  9. Germany Is the Engine: What BAT Knows That Cannabis Doesn't ft. James Yamanaka 41:49
  10. Why Ohio Cannabis Is Built Different: Inside the Regulator-Operator Alignment That's Actually Working ft. Caroline Henry 47:45
  11. Cannabis Was Medicine. Now the Proof Is Catching Up, ft. Joel Stanley and Dr. Marcel Bonn-Miller 50:37
  12. Joe Lustberg: What Cannabis Lenders See That Operators Miss 43:59
  13. The Hidden Margin Killer for MSOS ft. Braunz Muller 58:29
  14. Ed Rosenthal and Greg Baughman: You're Still Growing Cannabis Wrong 55:09
  15. The Legal Market Was Never Built for Payments, Why Cannabis Still Breaks the Rules ft. Aubrey Amatelli 40:30
  16. Gretchen Gailey: Cannabis Industry Has No Idea How DC Works, Why Rescheduling Is Delayed 52:43
  17. 15 Years of Cannabis Trading . Why I'll Sell Early (Unless This Happens) ft. Dan McDermitt 39:55
  18. Premium vs Scale in Cannabis: Inside Rubicon’s Strategy ft. Margaret Brodie 50:34
  19. Prop 64 Fine Print, Pesticide Drift, The Economics Behind Concentrates ft. Micah Anderson 53:54
  20. JB (Cheech & Chong CEO): Building a National Cannabis Brand Through Trial, Error & Partnership 45:06
  21. Cannabis Beverages Are Bringing New Consumers Into Cannabis ft Kristin & Eric Rogers 46:26
  22. Hidden Growth Unmasked: Rescheduling, the Farm Bill & What Comes Next ft Trent Woloveck 46:20
  23. Most Cannabis Marketing Fails Because It Is Asked to Solve the Wrong Problems ft. John Shute 47:40
  24. How Top Teams Balance Art and Process in Extraction ft. Brian Adams 43:25
  25. Robotics vs Automation in Cannabis Manufacturing ft. Nohtal Partansky 51:01
  26. Building Jaunty Into One of New York’s Top Cannabis Brands ft. Nicolas Guarino 56:57
  27. How Charlotte’s Web Unlocked Medical CBD ft. Bill Morachnick 49:59
  28. The Playbook Behind Consistent Cannabis Products at Scale ft. Ryan Crandall 46:42
  29. Schedule III Changes Everything — This Is Just the Beginning 38:13
  30. Inside SNDL’s Hidden Scale: Global Reach & Supply Chain Powerhouse ft. Tyler Robson 33:22
  31. You’re Thinking About Debt Wrong: The Secret to Smart Financing ft. Adam Stettner 53:52
  32. How LEVEL Delivers Effects-Based Cannabis Tablets ft. Chris Emerson 48:17
  33. What Tobacco and Alcohol Taught Me About Cannabis. ft. Nick Kenny 40:58
  34. The Amazon of THC, How Edibles.com Will Take Cannabis National, ft. Thomas Winstanley 52:57
  35. Introducing Singular: How Active's Modular Vape Platform Changes Everything ft. Alex Kwon 44:03
  36. The Lyft Playbook for Cannabis: Building Trust Through Tech ft. Ashwin Raj 48:05
  37. Built for Consolidation, Guided by Icahn-Like Discipline, and Poised for Cannabis’ Next Iteration, ft Jared Maloof 46:45
  38. Chris Ball: Betting It All — What It Really Takes to Build a Brand With Your Name on It: Pain, Patience, and Relentless Faith 56:26
  39. $28.4 Billion Dollar Hemp Industry Can’t Be Put Back in the Bottle ft Jim Higdon 47:52
  40. Largest Medical Cannabis & Cancer Study Ever: Can These Findings Push Rescheduling? ft Ryan Castle 48:40
  41. Strategy Truths & Lies, Mature Industries Already Know ft. Mitchell Osak 56:08
  42. THC Is an Ingredient, Where Pharma, MSOs & Hemp Collide, ft. Zach Edge 43:08
  43. Sensory Science Unlocked, Beyond THC, Inside True Terpenes ft. Dan Cook 51:32
  44. Dr. Greenhouse: The #1 Mistake Killing Your Plants ft. Nadia Sabeh 1:03:19
  45. Richie Proud on the iAnthus Turnaround: Why Selling Arizona Fueled Core-Market Growth 55:05
  46. Secrets Behind Failed Cannabis Builds: Where Every Team Needs to Look Now ft. David Fettner 49:36
  47. The ROI of Pre-Roll Automation: Scaling Quality, Reducing Labor, and Hitting 20K+ a Day ft. Shahar Yamay 39:00
  48. Keep Your Eye on Ohio: Why California’s Failures Are Michigan’s Success, and the Global Cannabis Landscape ft. Hirsh Jain 56:44
  49. The Cannabis Titanic: The Reset Ahead, Matt Karnes on What the Numbers Say 43:04
  50. Organigram’s Competitive Edge: Paolo De Luca on BAT, M&A Strategy, and the Cannabis Long Game 54:43